254 related articles for article (PubMed ID: 8016137)
1. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.
Engelhardt JF; Ye X; Doranz B; Wilson JM
Proc Natl Acad Sci U S A; 1994 Jun; 91(13):6196-200. PubMed ID: 8016137
[TBL] [Abstract][Full Text] [Related]
2. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a.
Engelhardt JF; Litzky L; Wilson JM
Hum Gene Ther; 1994 Oct; 5(10):1217-29. PubMed ID: 7849095
[TBL] [Abstract][Full Text] [Related]
3. Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study.
Goldman MJ; Litzky LA; Engelhardt JF; Wilson JM
Hum Gene Ther; 1995 Jul; 6(7):839-51. PubMed ID: 7578403
[TBL] [Abstract][Full Text] [Related]
4. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.
Yang Y; Nunes FA; Berencsi K; Furth EE; Gönczöl E; Wilson JM
Proc Natl Acad Sci U S A; 1994 May; 91(10):4407-11. PubMed ID: 8183921
[TBL] [Abstract][Full Text] [Related]
5. Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses.
Raper SE; Haskal ZJ; Ye X; Pugh C; Furth EE; Gao GP; Wilson JM
Hum Gene Ther; 1998 Mar; 9(5):671-9. PubMed ID: 9551615
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis.
Yang Y; Nunes FA; Berencsi K; Gönczöl E; Engelhardt JF; Wilson JM
Nat Genet; 1994 Jul; 7(3):362-9. PubMed ID: 7522742
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.
Lusky M; Christ M; Rittner K; Dieterle A; Dreyer D; Mourot B; Schultz H; Stoeckel F; Pavirani A; Mehtali M
J Virol; 1998 Mar; 72(3):2022-32. PubMed ID: 9499056
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver.
Lieber A; He CY; Meuse L; Himeda C; Wilson C; Kay MA
J Virol; 1998 Nov; 72(11):9267-77. PubMed ID: 9765474
[TBL] [Abstract][Full Text] [Related]
9. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.
Zhou H; O'Neal W; Morral N; Beaudet AL
J Virol; 1996 Oct; 70(10):7030-8. PubMed ID: 8794347
[TBL] [Abstract][Full Text] [Related]
10. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.
Gorziglia MI; Lapcevich C; Roy S; Kang Q; Kadan M; Wu V; Pechan P; Kaleko M
J Virol; 1999 Jul; 73(7):6048-55. PubMed ID: 10364357
[TBL] [Abstract][Full Text] [Related]
11. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.
Morral N; O'Neal W; Zhou H; Langston C; Beaudet A
Hum Gene Ther; 1997 Jul; 8(10):1275-86. PubMed ID: 9215744
[TBL] [Abstract][Full Text] [Related]
12. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses.
Dedieu JF; Vigne E; Torrent C; Jullien C; Mahfouz I; Caillaud JM; Aubailly N; Orsini C; Guillaume JM; Opolon P; Delaere P; Perricaudet M; Yeh P
J Virol; 1997 Jun; 71(6):4626-37. PubMed ID: 9151856
[TBL] [Abstract][Full Text] [Related]
13. Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs.
Fang B; Wang H; Gordon G; Bellinger DA; Read MS; Brinkhous KM; Woo SL; Eisensmith RC
Gene Ther; 1996 Mar; 3(3):217-22. PubMed ID: 8646552
[TBL] [Abstract][Full Text] [Related]
14. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
15. A Cre-expressing cell line and an E1/E2a double-deleted virus for preparation of helper-dependent adenovirus vector.
Zhou H; Zhao T; Pastore L; Nageh M; Zheng W; Rao XM; Beaudet AL
Mol Ther; 2001 Apr; 3(4):613-22. PubMed ID: 11319924
[TBL] [Abstract][Full Text] [Related]
16. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
17. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs.
Yang Y; Su Q; Wilson JM
J Virol; 1996 Oct; 70(10):7209-12. PubMed ID: 8794368
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products.
Christ M; Louis B; Stoeckel F; Dieterle A; Grave L; Dreyer D; Kintz J; Ali Hadji D; Lusky M; Mehtali M
Hum Gene Ther; 2000 Feb; 11(3):415-27. PubMed ID: 10697116
[TBL] [Abstract][Full Text] [Related]
19. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo.
Yang Y; Jooss KU; Su Q; Ertl HC; Wilson JM
Gene Ther; 1996 Feb; 3(2):137-44. PubMed ID: 8867861
[TBL] [Abstract][Full Text] [Related]
20. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy.
Gao GP; Yang Y; Wilson JM
J Virol; 1996 Dec; 70(12):8934-43. PubMed ID: 8971023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
